First Tracks Biotherapeutics (TRAX *) Stock Overview

Operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. More details

TRAX * fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

TRAX * Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

First Tracks Biotherapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for First Tracks Biotherapeutics
Historical stock prices
Current Share Price	US$317.30
52 Week High	US$0
52 Week Low	US$0
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	TRAX *	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how TRAX * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how TRAX * performed against the MX Market.

Price Volatility

Is TRAX *'s price volatile compared to industry and market?
TRAX * volatility
TRAX * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: TRAX *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine TRAX *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2019	104	Dan Faga	www.firsttracksbio.com

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026.

First Tracks Biotherapeutics, Inc. Fundamentals Summary

How do First Tracks Biotherapeutics's earnings and revenue compare to its market cap?
TRAX * fundamental statistics
Market cap	Mex$10.38b
Earnings (TTM)	-Mex$2.93b
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.5x

P/E Ratio

Is TRAX * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRAX * income statement (TTM)
Revenue	US$0
Cost of Revenue	US$139.61m
Gross Profit	-US$139.61m
Other Expenses	US$29.76m
Earnings	-US$169.37m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-4.85
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did TRAX * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/25 08:48
End of Day Share Price	2026/04/27 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

First Tracks Biotherapeutics, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Etzer Darout	Barclays
Emily Bodnar	H.C. Wainwright & Co.
Anupam Rama	J.P. Morgan